Pose the naive question a smart friend would ask: if CRISPR Therapeutics helped invent the first approved CRISPR therapy, why do you keep hearing Vertex's name attached to it? The short version is that co-inventing a drug and controlling its commercial life are two different things — and CRISPR Therapeutics' own filings draw that line clearly.
Think of it like a song written by two people where one of them owns the record label. In its 2025 annual report (10-K, filed February 12, 2026), CRISPR Therapeutics lists among its risks that it collaborates with Vertex on its lead program Casgevy and that Vertex has significant control over the Casgevy program. That is the company telling its own shareholders, in plain risk-factor language, who holds the steering wheel.
The trademark detail makes it concrete. Across CRISPR Therapeutics' filings — the 10-K, its first-quarter 2026 10-Q, and its proxy statement — there is a recurring legal notice that CASGEVY and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals. In plain terms: the brand name patients and doctors see belongs to Vertex, even though CRISPR Therapeutics co-created the underlying medicine.
Why does this matter beyond legal trivia? Because control shapes economics. A third-quarter 2025 10-Q reiterates that Casgevy, approved in 2023, became the first-ever approved CRISPR-based gene-editing therapy in the world — a genuine scientific milestone for CRISPR Therapeutics. But when a partner controls the program and owns the brand, the originating company's slice of the upside and its say over launch decisions are defined by the collaboration agreement, not by who first edited the gene.
The crosswalk, then, connects one scientific fact to one business fact. Scientific fact: CRISPR Therapeutics co-invented a first-in-class gene-editing cure for sickle cell disease and beta thalassemia. Business fact, from its filings: Vertex has significant control and holds the trademark. Both are true, and only reading the disclosure resolves the apparent tension.
The EdgarBeast evidence index makes this easy to verify — the same trademark notice and the same significant control risk language appear across multiple CRISPR Therapeutics filings, so a reader can confirm the relationship from the primary documents rather than from a press release. The lesson generalizes: in biotech partnerships, who invented it and who runs it are separate questions, and the filing answers the second.